Schizophrenia 6

Common Name(s)

Schizophrenia 6

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Schizophrenia 6" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Schizophrenia 6" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Schizophrenia 6" returned 39 free, full-text research articles on human participants. First 3 results:

The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia.
 

Author(s): Kayla A Chase, Jackson J Cone, Cherise Rosen, Rajiv P Sharma

Journal:

 

Associations between a pro-inflammatory state and schizophrenia have been one of the more enduring findings of psychiatry, with various lines of evidence suggesting a compelling role for IL-6 in the underlying pathogenesis of schizophrenia.

Last Updated: 21 May 2016

Go To URL
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.
 

Author(s): Susana Conde-Ceide, Jesús Alcázar, Sergio A Alonso de Diego, Silvia López, María Luz Martín-Martín, Carlos M Martínez-Viturro, Miguel-Angel Pena, Han Min Tong, Hilde Lavreysen, Claire Mackie, Thomas M Bridges, J Scott Daniels, Colleen M Niswender, Carrie K Jones, Gregor J Macdonald, Thomas Steckler, P Jeffrey Conn, Shaun R Stauffer, Craig W Lindsley, José Manuel Bartolomé-Nebreda

Journal: Bioorg. Med. Chem. Lett.. 2016 Jan;26(2):429-34.

 

As part of our efforts to identify a suitable back-up compound to our recently disclosed mGlu5 positive allosteric modulator (PAM) clinical candidate VU0490551/JNJ-46778212, this letter details the investigation and challenges of a novel series of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one ...

Last Updated: 8 Jan 2016

Go To URL
Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up.
 

Author(s): Tina Behdinan, George Foussias, Anne L Wheeler, Laura Stefanik, Daniel Felsky, Gary Remington, Tarek K Rajji, M Mallar Chakravarty, Aristotle N Voineskos

Journal: Schizophr. Res.. 2015 Dec;169(1-3):69-75.

 

Studies show that deficit syndrome schizophrenia patients, characterized by primary negative symptoms and poor functional outcome, have impairment in specific neural circuits. We assessed whether these same neural circuits are directly linked to functional outcomes across schizophrenia patients.

Last Updated: 16 Dec 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Schizophrenia 6" returned 2 free, full-text review articles on human participants. First 3 results:

Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.
 

Author(s): Matcheri S Keshavan, Henry A Nasrallah, Rajiv Tandon

Journal: Schizophr. Res.. 2011 Apr;127(1-3):3-13.

 

The current construct of schizophrenia as a unitary disease is far from satisfactory, and is in need of reconceptualization. The first five papers in our "facts" series reviewed what is known about schizophrenia to date, and a limited number of key facts appear to stand out. Schizophrenia ...

Last Updated: 8 Mar 2011

Go To URL
Schizophrenia and alterations in self-experience: a comparison of 6 perspectives.
 

Author(s): Paul H Lysaker, John T Lysaker

Journal: Schizophr Bull. 2010 Mar;36(2):331-40.

 

Contemporary researchers have tended to examine dysfunction among the lives of persons with schizophrenia as a matter of the impact of biological and social forces. While this has greatly advanced the knowledge base, any account of schizophrenia without a full consideration of the ...

Last Updated: 8 Mar 2010

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia
 

Status: Not yet recruiting

Condition Summary: Schizophrenia

 

Last Updated: 25 Aug 2016

Go to URL
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
 

Status: Recruiting

Condition Summary: Schizophrenia

 

Last Updated: 24 Jan 2017

Go to URL
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
 

Status: Recruiting

Condition Summary: Schizophrenia

 

Last Updated: 10 Apr 2017

Go to URL